Skip to main content

September 2025

Crack GPAT — Prepare for GPAT Online 

THSTI Openings for Life Sciences candidates - 09 Openings

Masters degree in any branch of Life Sciences from a recognized university with atleast eight years of post-qualification experience in R&D in Industrial and Academic Institutions or Science and Technology
Openings for Life sciences, Biotechnology and Microbiology at Agharkar Research Institute
Integrated MSc in life sciences including Zoology, Biotechnology and Microbiology with 55% marks.
Openings for D.Pharm, B.Pharm, M.Pharm, MSc in Injectable Manufacturing at Amneal Pharma
Experience in production planning, change control, line clearance, deviation handling, autoclave operation, aseptic and control area operation, documentation, both SVP and LVP manufacturing etc. 
Interview for M.Pharm, B.Pharm, MSc in Production, QA, QC, Packing at Hetero
Interview for M.Pharm, B.Pharm, M.Sc, B.Sc ; Stability, HPLC, GC, Wet Analysis, Dissolution, IP/FP, RM, LIMS, Microbiology.
Interview for D.Pharm, B.Pharm in Production, Packing at Ipca Laboratories
Relevant experience in operation and supervision of CAM | IMA | Blister | CVC | Cartonator | Documentation (QMS) for Packing Dept.
Opportunity for R&D Analytical Function at Troikaa Pharma
M.Pharm / M.Sc by education with 5+ years experience into Analytical Method Validation, Method Developments Regulatory query response.
Hiring Drug Safety Executive at Fidelity Health Services
Perform accurate Book-in and data entry ICSRs into safety databases within defined timelines. Ensure compliance with regulatory guidelines, SOPs, and company quality standards for PV processes.
Openings in Production, QA, QC at Rusan Pharma
Rusan is a research driven pharmaceutical company having its Manufacturing Units in India and Worldwide Marketing of Pharmaceutical Formulation, Active Pharmaceutical Ingredients and Intermediates.
FDA rejects Otsuka and Lundbeck’s bid for REXULTI® in PTSD Treatment
Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the supplemental New Drug Application (sNDA) for the use of REXULTI® (brexpiprazole) in combination with sertraline for the treatment of adults with post-traumatic stress disorder (PTSD).
FDA Grants Accelerated Approval to First Treatment for Barth Syndrome
U.S. Food and Drug Administration granted accelerated approval to Forzinity (elamipretide) injection as the first treatment for Barth syndrome, in patients weighing at least 30 kg. Barth syndrome is a rare, serious and life-threatening disease of the mitochondria.